Associations between the CADM2 gene, substance use, risky sexual behavior, and self-control: A phenome-wide association study

Rachel M. Arends1,2,3 | Joëlle A. Pasman4 | Karin J.H. Verweij5 | Eske M. Derks6 | Scott D. Gordon6 | Ian Hickie7 | Nathaniel S. Thomas8 | Fazil Aliev9,10 | Brendan P. Zietsch11 | Matthijs D. van der Zee12,13 | Brittany L. Mitchell14,15 | Nicholas G. Martin6,11 | Danielle M. Dick8 | Nathan A. Gillespie6,11,16 | Eco J.C. de Geus5,13 | Dorret I. Boomsma5,12,13 | Arnt F.A. Schellekens1,2,17 | Jacqueline M. Vink4

1Department of Psychiatry, Radboud University Medical Center, The Netherlands
2Donders Center for Medical Neuroscience, Donders Institute for Brain, Cognition and Behavior, The Netherlands
3Tactus Addiction Care, The Netherlands
4Behavioural Science Institute, Radboud University, The Netherlands
5Faculty of Medicine, Amsterdam Medical Centre and University of Amsterdam, The Netherlands
6Genetic Epidemiology, Statistical Genetics and Translational Neurogenomics Laboratories, QIMR Berghofer Medical Research Institute, Australia
7Brain and Mind Centre, University of Sydney, Australia
8Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA
9Faculty of Business, Karbüük University, Turkey
10Department of African American Studies, Virginia Commonwealth University, Richmond, VA, USA
11School of Medicine and School of Psychology, University of Queensland, Australia
12Department of Biological Psychology, Vrije Universiteit Amsterdam, The Netherlands
13Netherlands Twin Register, The Netherlands
14Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Australia
15School of Biomedical Sciences and Institute of Health and Biomedical Innovation, Queensland University of Technology, Australia
16Virginia Institute for Psychiatric and Behavior Genetics, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA
17Nijmegen Institute for Scientist-Practitioners in Addiction, The Netherlands

Abstract
Risky behaviors, such as substance use and unprotected sex, are associated with various physical and mental health problems. Recent genome-wide association studies indicated that variation in the cell adhesion molecule 2 (CADM2) gene plays a role in risky behaviors and self-control. In this phenome-wide scan for risky behavior, it was tested if underlying common vulnerability could be (partly) explained by pleiotropic effects.
effects of this gene and how large the effects were. Single nucleotide polymorphism (SNP)-level and gene-level association tests within four samples (25 and Up, Spit for Science, Netherlands Twin Register, and UK Biobank and meta-analyses over all samples (combined sample of 362,018 participants) were conducted to test associations between CADM2, substance- and sex-related risk behaviors, and various measures related to self-control. We found significant associations between the CADM2 gene, various risky behaviors, and different measures of self-control. The largest effect sizes were found for cannabis use, sensation seeking, and disinhibition. Effect sizes ranged from 0.01% to 0.26% for single top SNPs and from 0.07% to 3.02% for independent top SNPs together, with sufficient power observed only in the larger samples and meta-analyses. In the largest cohort, we found indications that risk-taking proneness mediated the association between CADM2 and latent factors for lifetime smoking and regular alcohol use. This study extends earlier findings that CADM2 plays a role in risky behaviors and self-control. It also provides insight into gene-level effect sizes and demonstrates the feasibility of testing mediation. These findings present a good starting point for investigating biological etiological pathways underlying risky behaviors.

**KEYWORDS**

CADM2, multi-cohort, phenome-wide, risky behavior, self-control, substance use

---

1 | **INTRODUCTION**

Risky behaviors, such as substance use (e.g., nicotine, alcohol, and cannabis) and unprotected sexual contact, are important factors contributing to physical and mental health problems. As a result, these risk factors for morbidity and mortality are included in the global Sustainable Development Goals, set up and agreed on by all member states of the United Nations in 2015 to ensure more healthy lives and promote quality of life worldwide. For instance, substance use contributes to approximately 12% of deaths worldwide, due to factors such as an increased risk of respiratory and vascular diseases, various forms of cancer, stroke, suicide, or overdose. Approximately 4% of the global burden of disease, as measured in disability-adjusted life years (DALYs), is attributable to alcohol and tobacco use and 0.8% to illicit drugs. Furthermore, risky sexual behavior (e.g., unprotected sexual intercourse with multiple partners) contributes another 6.3% of the total global burden of disease, as it is associated with the risk of sexually transmitted infections (STIs), human immunodeficiency virus (HIV), or cervical cancer. Various studies indicate that risky behavior has a substantial genetic component. For instance, a substantial part of the variation in the initiation of substance use can be explained by genetic factors: alcohol (37%), nicotine (44%), and cannabis (40%–48%). Even higher heritability estimates are shown for substance use disorders, for example, alcohol: 45%–73%, nicotine: 44%–75%, and cannabis: 37%–59%. Furthermore, the heritability of risky sexual behavior was estimated by previous research to be around 33%. It is assumed that different risky behaviors might merely reflect different phenotypic manifestations of (partly) shared underlying genetic vulnerabilities. However, it is largely unknown which genetic and biological mechanisms underpin the heritability of risky behaviors.

Recent large genome-wide association studies (GWASs) have independently implicated a gene located on chromosome 3 encoding cell adhesion molecule 2 (CADM2) in various risky behaviors including alcohol (ab)use, lifetime cannabis use, number of sexual partners, and age at first sexual intercourse. Proteins encoded by CADM2 are involved in glutamate signaling, GABA transport, and neuron cell-cell adhesion, especially in the prefrontal and anterior cingulate cortices. These brain regions are well known for their role in cognitive control and motivational salience, which are in turn involved in impulse regulation and self-control.

Low self-control, as indexed by high impulsivity, sensation seeking, and disinhibition, has been associated with engaging in risky behavior, including unprotected sexual intercourse and substance use (initiation) or abuse. A review by Bezdjian et al. showed heritability for different indices of self-control of around 50% across 41 studies including around 27,000 infants, children, adolescents, and adults. These findings suggest that genetic factors, at least in part, modulate various aspects of self-control. Specifically, CADM2 has been associated with sensation seeking and impulsivity. This suggests potential shared heritability between reduced self-control and risky behavior, most likely due to overlapping underlying biological processes. As such, reduced self-control might act as intermediate phenotype, linking CADM2 and various risky behaviors.
Candidate-gene studies have traditionally selected plausible candidate-genes based on a theory on the underlying biological mechanisms, for example, relating the dopamine cascade to ADHD or substance use. This approach is limited by current knowledge of the biology of investigated behaviors. In addition, candidate-gene studies are often restricted by a lack of available data resulting in underpowered or small-scale designs and examination of only a few (or a single) phenotype(s). Consequently, these limitations have rendered the candidate-approach largely unsuccessful.

We propose to apply GWAS techniques on a single gene, whose candidate-gene status is anchored in a body of (hypothesis-free) GWASs. In this first phenome-wide association study (PHeWAS) for CADM2 and risky behavior, the multiple testing burden is much lower than in GWASs, which should increase power. This study aims to establish if power increases substantially enough to detect associations in smaller samples, thereby also providing insight into gene-level effect sizes. By looking at several risky behavior phenotypes concurrently, we furthermore investigate the link between genetic variation in CADM2 and substance- and sex-related risk behaviors more comprehensively than single phenotype studies. Doing so, we aim to examine if the involvement of CADM2 in various risky behaviors and self-control related constructs (i.e., pleiotropy, when a single gene influences the expression of multiple phenotypic traits) can explain the potential genetic overlap between various aspects of reduced self-control and multiple risky behaviors. By combining data from four different cohorts and analyzing a range of risky behaviors and indices of self-control, we aim to increase reliability and robustness of findings. Finally, we explore if reduced self-control might mediate the relationship between CADM2 and various risky behaviors.

In data across four European ancestry population-based samples from different countries, we tested here whether single nucleotide polymorphisms (SNPs) in CADM2 are associated with risk behavior, including (1) substance use and abuse (alcohol, tobacco, cannabis, and other drugs), (2) sexual risk behavior (number of sex partners, sexual risk-taking, and age at first sexual intercourse), and (3) indices of reduced self-control (disinhibition, sensation seeking, risk-taking proneness, and ADHD symptoms). We conduct factor analyses to explore common underlying vulnerability factors. Furthermore, we explore whether relationships between CADM2 and risk behaviors are mediated by a self-control trait.

# MATERIALS AND METHODS

## Subjects and procedures

Data from 443,693 participants from four different data sources were used, including the Queensland Twin Registry’s “25 and Up” (25Up: \( N = 2,133 \)) study in Australia, “Spit for Science” (S4S: \( N = 2,994 \)) study in the USA, the “Netherlands Twin Register” (NTR: \( N = 12,120 \)) repository in The Netherlands, and the “UK Biobank” (UKB: \( N = 426,446 \)) in the United Kingdom. Although 25UP and S4S are considerably smaller than the others, they have not been included in previous risk behavior GWAS and have data on phenotypes that were not available in NTR and UKB, making them valuable additions. All studies were performed in accordance with the Declaration of Helsinki and were approved by local ethical committees. Study details are described in articles referenced in the Supplementary Methods section.

## Measures

### Genotyping and quality control

We used available genotyped or imputed SNP information in and around CADM2 (chr 3 (3p12.1), bp 83,951,945-86,126,470, GRCh37/hg19). Per sample genotyping, imputation and quality control (QC) procedures can be found in Table S1. Variants with a minor allele frequency (MAF) below 1%, a genotype missingness rate above 5%, or deviations from Hardy–Weinberg Equilibrium (HWE) of \( p < 1e-10 \) were excluded from further analysis. SNPs were aligned with the 1,000 Genomes reference panel (phase 3), removing ambiguous SNPs and SNPs that had a MAF that diverged more than 0.15 from that in the reference panel. Following these procedures, \( n_{25Up} = 297, n_{S4S} = 2,972, n_{NTR} = 6,166, \) and \( n_{UKB} = 4,638 \) SNPs were available and retained for analysis. Genetic data and data on at least one phenotype were available for \( N_{25Up} = 2,133, N_{S4S} = 2,994, N_{NTR} = 12,120, \) and \( N_{UKB} = 426,446 \) individuals (total \( N = 443,693 \)). The per-phenotype sample size range was \( N_{25Up} = 419-2,071, N_{S4S} = 503-2,384, N_{NTR} = 581-9,432, \) and \( N_{UKB} = 23,423-362,018 \) individuals.

### Outcome measures

In this study, we adopted a PHeWAS approach, meaning that we tested the association between CADM2 and all risk behavior and self-control measures that were available in the datasets. In order to provide an overview of all measures, we grouped them into six categories: lifetime experience with substance use (regarding tobacco, cannabis, and other substances), age at initiation of substance use (regarding alcohol, tobacco, cannabis, and other substances), average substance use level (regarding alcohol and tobacco), regular substance (ab)use (including regular alcohol, tobacco, and cannabis use and any behavioral/substance addiction), sexual risk behavior (including the number of sexual partners, sexual risk-taking, and age at first sexual intercourse), and self-control (including disinhibition, sensation seeking, risk-taking proneness, and symptoms of ADHD). Variables with a total \( N \) of < 1,000 were excluded as they could not be analyzed due to a lack of statistical power. Preprocessing of the data included combining measures (e.g., across different waves), removing outliers, and excluding inconsistent or invalid response patterns. An overview of all 23 outcome measures included can be found in Table 1. More detailed
TABLE 1  Descriptive statistics of participant characteristics and study variables for the four cohort studies

| Variable                                      | 25Up (N = 2,133) | S4S (N = 2,994) | NTR (N = 12,120) | UKB (N = 426,446) |
|-----------------------------------------------|------------------|-----------------|------------------|-------------------|
|                                               | N | Range/n | M (SD) / % | N | Range/n | M (SD) / % | N | Range/n | M (SD) / % | N | Range/n | M (SD) / % |
| **Demographics**                              |              |                 |                |              |                 |                |              |                 |                |              |                 |
| **Age**                                       | 2,131 | 21.8–44.2 | 30.1 (4.3) | 2,452 | 18.1–32.1 | 20.7 (1.5) | 12,013 | 18.0–94.0 | 44.8 (16.9) | 426,446 | 36.0–72.0 | 54.7 (8.0) |
| **% Male**                                    | 2,133 | 832     | 39.0%       | 2,452 | 1,255     | 41.9%       | 12,013 | 295       | 3.1%       | 426,446 | 75,577    | 17.7%       |
| **% No/primary education**                     | 2,132 | 250     | 11.7%       | 2,452 | 5         | 0.2%       | 12,013 | 2,954     | 20.6%      | 426,446 | 114,042  | 26.7%       |
| **% Secondary education**                      | 572    | 26.8%   | 572          | 2,452 | 238       | 8.0%       | 12,013 | 1,954     | 20.6%      | 426,446 | 114,042  | 26.7%       |
| **% Certificate or diploma**                   | 890    | 41.7%   | 890          | 2,452 | 425       | 14.3%      | 12,013 | 2,892     | 30.5%      | 426,446 | 98,540   | 23.1%       |
| **% Masters/postgraduate/PhD**                 | 420    | 19.7%   | 420          | 2,452 | 2,295     | 77.5%      | 12,013 | 4,330     | 45.7%      | 426,446 | 138,287  | 32.4%       |
| **Lifetime substance use**                    |       |         |             |       |           |             |       |           |             |       |           |             |
| **% Ever used tobacco**                        | 2,128 | 1,496   | 70.3%       | 2,876 | 1,949     | 67.8%      | 11,870 | 5,745     | 48.4%      | 425,114 | 259,676 | 61.1%       |
| **% Ever used cannabis**                       | 2,118 | 1,331   | 62.8%       | 2,953 | 1,966     | 66.6%      | 10,012 | 2,412     | 24.1%      | 30,627  | 30,627   | 22.1%       |
| **% Ever used other substance(s)**             | 2,062 | 1,104   | 53.5%       | 2,968 | 1,067     | 36.0%      | 10,055 | 1,153     | 11.5%      | NA      | NA       | NA          |
| **Age at initiation of substance use**         |       |         |             |       |           |             |       |           |             |       |           |             |
| **M age alcohol initiation**                   | 1,995 | 11–22   | 16.5 (1.8)  | 9,762 | 11–30     | 15.8 (2.1) | NA      | NA        | NA         | NA      | NA       | NA          |
| **M age tobacco initiation**                   | 471   | 11–21   | 15.9 (2.0)  | 6,862 | 11–30     | 15.4 (2.3) | 32,381  | 11–69     | 17.9 (5.7) | NA      | NA       | NA          |
| **M age cannabis initiation**                  | 1,275 | 11–19   | 14.4 (2.0)  | 9,729 | 11–40     | 17.9 (3.3) | NA      | NA        | NA         | NA      | NA       | NA          |
| **M age other substance initiation**           | 1,037 | 11–24   | 15.1 (2.1)  | 11,381 | 11–40     | 21.4 (5.2) | NA      | NA        | NA         | NA      | NA       | NA          |
| **Average substance use**                     |       |         |             |       |           |             |       |           |             |       |           |             |
| **M alcohol units per month**                  | 1,929 | 0–199   | 23.1 (30.4) | 8,670 | 0–192     | 34.9 (27.3) | 304,654 | 0–200     | 8.8 (7.8)  | NA      | NA       | NA          |
| **M cigarettes per day**                      | 430   | 0–30    | 1.3 (0.6)   | 4,819 | 0–60      | 13.8 (9.4)  | 132,310 | 1–140     | 18.3 (10.1) | NA      | NA       | NA          |
| **M tobacco using days**                       | 430   | 1–30    | 6.4 (8.5)   | 2,016 | 4–30      | 23.7 (9.9)  | NA      | NA        | NA         | NA      | NA       | NA          |
| **Regular substance (abuse)**                 |       |         |             |       |           |             |       |           |             |       |           |             |
| **% Regular alcohol use**                     | 2,062 | 450     | 21.8%       | 2,662 | 220       | 8.3%       | 11,081 | 2,722     | 24.6%      | 138,693 | 42,564   | 30.7%       |
| **M problematic alcohol use (AUDIT)**         | NA     | NA      | NA          | 2,603 | 0–11      | 3.5 (2.7)  | 6,248  | 0–34      | 4.1 (3.6)  | 138,682 | 0–39     | 5.0 (4.2)   |
| **% Regular tobacco use**                     | 1,490 | 489     | 32.8%       | 2,979 | 427       | 14.3%      | 8,051  | 2,386     | 29.6%      | 299,866 | 133,640  | 44.6%       |
| **M nicotine dependence (FTND)**              | NA     | NA      | NA          | 1,553 | 0–9       | 1.1 (1.9)  | 4,475  | 0–10      | 2.8 (2.4)  | 132,541 | 0–9      | 1.8 (1.9)   |
| **% Regular cannabis use**                    | 1,317 | 303     | 23.0%       | 2,953 | 397       | 13.4%      | 1,493  | 232       | 15.5%      | 29,704  | 10,465   | 35.2%       |
| **% Any behavioral/substance addiction**      | NA     | NA      | NA          | NA     | NA        | NA         | NA     | NA        | NA         | 137,122 | 8,278    | 6.0%        |
| **Sexual risk behavior**                      |       |         |             |       |           |             |       |           |             |       |           |             |
| **M number of sexual partners**               | 1,719 | 0–300   | 13.3 (24.4) | 1,023 | 0–25      | 1.3 (1.8)  | NA     | NA        | NA         | 351,099 | 1–300    | 6.6 (130)   |
| **M/% sexual risk behavior**                  | 1,925 | 0–10    | 2.1 (2.4)   | 1,014 | 375       | 37.0%      | NA     | NA        | NA         | NA      | NA       | NA          |
| **M age at first sexual intercourse**          | NA     | NA      | NA          | 919   | 11–28     | 16.3 (3.1) | 1,071  | 12–18     | 17.1 (1.2) | 375,311 | 11–69    | 19.1 (3.8)  |
information about the (cleaning and combining of the) measures is given in Table S2.

2.3 Data analysis

Primary analyses were performed separately within each cohort and combined in meta-analyses. Identical analysis procedures were used in all individual datasets. Phenotype data cleaning, preparation, and descriptive analyses were conducted using the Statistical Package for the Social Sciences (SPSS; version 25).38

To test whether CADM2 SNPs were associated with separate risk behavior outcomes, association analyses were firstly conducted in PLINK (version 1.9).39 For dichotomous phenotypes, logistic regression was used; for continuous variables, we used linear regression. Covariates included sex, age, and highest level of education, as we aimed to capture the influence of CADM2 on risk behavior and self-control that was independent of these factors (e.g., education has shown to be associated both with CADM2 and risk behavior).40 Furthermore, principal components (PCs) for ancestry were included. PCs are used to control for possible stratification effects that arise when a genetic factor and a trait show a spurious correlation due to systematic differences in allele frequencies between groups of different genetic ancestry. We used the PCs as calculated by the institute we received the data from, following their recommendations on how many PCs were appropriate to control for ancestry stratification effects within their specific sample. Because S4S participants were recruited at university, parental rather than own education level was included as a covariate in this sample. In 25Up, S4S, and NTR we used 10 PCs to control for population stratification, while in UKB we included 40 PCs. We controlled for clustering due to genetic relatedness in the twin datasets (25Up and NTR) by using the family option in PLINK and excluded individuals that showed high genetic relatedness in the other datasets (see Table S1).

Thirdly, we conducted two meta-analyses for those phenotypes that were present in multiple datasets in order to maximize power to detect associations. The first meta-analysis was performed on the results from the per-cohort gene-based tests using the meta-analysis procedure in MAGMA. This method aggregates the Z-values for the gene-based associations within the individual cohorts while taking
sample size into account, in a procedure similar to “normal” meta-
alysis. The results give an indication of the strength of the associa-
tion with CADM2 across cohorts. The second meta-analysis was used
to get per-SNP effects that can be used to estimate the variance in
the phenotype explained by SNPs in the gene ($R^2$). To conduct these
meta-analyses, odds ratios for binary outcome variables were
converted to betas with corresponding standard errors in the input
files and all continuous variables were standardized. The meta-analysis
was conducted in METAL based on standard errors and effect esti-
mates (rather than on sample size) so that $\beta$ and se($\beta$) could be
obtained.

Using the results from the SNP-based meta-analysis, we com-
puted $R^2$ (the procedure is described in Supplementary Methods II).
To give an indication of how the resulting effect size estimates
impacted power, we conducted post-hoc power analyses for the
meta-analysis. The analysis was conducted based on the observed
effect sizes as a function of the minimum and maximum sample size.
We used the compromise power analysis option from the G*power
package for the $F$ test family with a single predictor.

### 2.3.1 | Mediation analysis with latent factors

A secondary aim of this study was to test whether the association
between CADM2 and risky behavior would be mediated by one or
more indices of self-control. Assuming that latent factors would be
stronger measures of underlying risky behavior propensity than the
separate phenotypes (and to limit the number of analyses), we used
factor scores in the mediation analyses. Assuming that CADM2 is
associated with risky behavior and reduced self-control in general
rather than specific behaviors or constructs per se, such latent fac-
tors might show stronger relationships with CADM2. We used a
data-driven approach without a priori specifying the nature of the
factors or the number of factors to extract. We expect clustering due
to the overlap in the measures, but the actual clustering could differ
per sample. We used PC analysis with principal axis factoring
(PAF/PFA) including oblique (oblimin) rotation; missing values were
replaced with the mean. The analyses were conducted separately
for each cohort and factors with an Eigenvalue $>1$ that explained
$>10\%$ of the variance were extracted from the dataset (see
Table S3). Subsequently, individual factor scores were computed
using regression.

To test if a self-control trait can explain the association between
CADM2 and risky behavior, we tested mediation following Baron and
Kenny’s procedure (see Figure 1, including $p$-values rather than
regression weights as MAGMA does not provide such estimates).
We first tested the relationship between CADM2 and the risk behav-
ior factor (path $c$) in MAGMA, and if that was significant, we tested
the association between the self-control trait (mediator) and the risk
behavior factor in SPSS (path $b$). If path $b$ and path $c$ were significant,
and there was an association between a self-control trait and CADM2
in the gene-based test (path $a$), we tested in a final step the relation-
ship between CADM2 and the risk behavior factor outcome, while
controlling for the self-control mediator, in MAGMA (path $c$). When
in path $c$ the relationship between the risk behavior and CADM2 was
attenuated while controlling for self-control, mediation was
assumed. In all paths, we controlled for the effects of age, sex, and
education, and in the analyses involving genetic data, we controlled
for the PCs.

As an addition to see if common propensity would indeed show a
stronger association with CADM2, we also meta-analyzed factors that
were made up of similar indicators in different cohorts. We used simi-
lar procedures for these analyses as for the separate phenotypes in
MAGMA.

![Figure 1](image-url)

**FIGURE 1** Significance of associations between CADM2 and risk behavior factors, with and without a mediating effect of risk-taking
proneness. Path $a$: the effect of the predictor (CADM2) on the mediator (risk-taking proneness); path $b$: the effect of the mediator on the outcome
factors (tobacco (ab)use, lifetime smoking, and risky alcohol use); path $c$: the effect of the predictor on the outcome variables; path $c'$: the effect of
the predictor on the outcome variables controlling for the mediator. $\dagger$ $C'$ paths with attenuated $p$-values, indicating a partial mediation effect
3 | RESULTS

3.1 | Demographics and descriptives

The sample size of people included in at least one analysis consisted of 443,693 individuals (maximum sample size per analysis N = 362,018). Slightly more than half of the participants (54%) were female (25Up: 61%, S4S: 58%, NTR: 62%, UKB: 54%), and age ranged from 18 to 94 with a weighted mean age of 38 years (25Up: M = 30.1, SD = 4.3; S4S: M = 20.7, SD = 1.5; NTR: M = 44.8, SD = 16.9; UKB: M = 54.7, SD = 8.0). Furthermore, most participants had a moderate (49%) or high (33%) level of education (largest group 25Up: 41.7% moderately high, S4S: 77.5% high, NTR: 45.7% high, UKB: 32.4% high education).

Cohort descriptions are provided in Table 1, including a description of the mean (continuous variables) and prevalence rates (dichotomous variables) for all outcome measures. Due to different operationalizations and sample compositions in the four cohorts, most descriptives cannot be directly compared. In the association analyses, we controlled for age, sex, and education level, and we conducted meta-analysis either on per-sample Z-scores for the association (in MAGMA) or on standardized regression weights (in METAL) to control for sample differences.

3.2 | Associations for CADM2 with risk behavior and self-control

The associations between CADM2 and risk behavior and indices of self-control are shown in Table 2. Associations that were significant after FDR-correction for multiple testing (at $p < .05$) are indicated with an asterisk. Both lifetime tobacco use and lifetime cannabis use were associated with CADM2 in the meta-analyses. In the individual samples, these associations were significant in NTR and UKB but not in 25Up and S4S. No significant associations were found for lifetime use of other substances (i.e., recreational drugs), although it must be noted that this variable was not present in the largest sample (UKB). None of the age at initiation of substance use variables were associated with CADM2. The smallest p-value was 0.049 in the NTR sample for age at alcohol initiation. After correction for multiple testing, this finding was no longer significant. The meta-analyses revealed associations between both average alcohol consumption and average number of cigarettes per day and CADM2 that seem to be largely driven by significant associations in the UKB sample. Regular alcohol use, problematic alcohol use, regular tobacco use, and nicotine dependence were all associated with CADM2 in the meta-analyses. In the individual study analyses, only regular alcohol use was after correction significantly associated with CADM2 in a sample (S4S) other than the UKB. The number of sexual partners was associated with CADM2 in 25Up, UKB and the meta-analysis, and age at first sexual intercourse in UKB and the meta-analysis but not in the individual 25Up, S4S, or NTR samples.

As for the analyses of indices of self-control, a significant association between CADM2 and disinhibition (significant in the NTR and meta-analysis), sensation seeking (in NTR), and risk-taking personality (in UKB) was observed. As the constructs of sensation seeking and risk-taking personality were only measured in one study, no meta-analyses could be performed.

SNP-based meta-analyses were conducted in order to get per-SNP estimates that could be used to compute explained variances. Results show little overlap between the top-SNPs for different phenotype-sets (see Table S4). Only 31 SNPs showed a significant association with multiple independent phenotypes.

3.2.1 | Effect sizes of the associations and power analyses

The variance explained by all independently associated SNPs in CADM2 taken together ranged from 0.07% for regular alcohol use to 3.02% for regular cannabis use ($M = 1.05\%$, $SD = 1.09\%$, $Mdn = 0.45\%$). The sample sizes included in the analyses ranged from 2,094 to 362,018 individuals (see Table 2). It does not seem to be the case that phenotypes from a particular sample or specific category have higher $R^2$ than the others. Also, there does not seem to be an effect of the number of SNPs in the analysis on the size of $R^2$ ($r = -0.27, p > 0.05$).

As most effect sizes were below 1%, we set the power analysis parameters at $R^2 = 0.001%$ to 1% as a range for the effect size and 2,000–400,000 as a range for the sample size. For an effect size of 0.001% even a sample size of 400,000 results in a power level of only 50%, whereas for an effect size of 1% a sample size of 8,000 suffices to achieve 80% power. In our study, the average observed effect size of the top SNP was $R^2 = 0.11\%$, resulting in sufficient (>80%) power levels at sample sizes of at least $N = 7,100$. A visualization of power as a function of effect size and the SNP sample size is provided in Figure S1A,B.

3.2.2 | Mediation analysis with latent factors

Factor analysis of the 14–20 outcomes per sample overall identified five factors with Eigenvalues above 1 and explained variance >10%, of which two appeared to be made up by similar variables in multiple cohorts (see Table S3). The latent factor lifetime substance use was present in 25Up and S4S and was not significantly associated with CADM2. A tobacco (ab)use factor could be discerned in all datasets but was only significantly associated with CADM2 in UKB with $p = 8.45e-06$. In UKB there were two other factors, one for lifetime smoking and one for regular alcohol use, which were both associated with CADM2 ($p = 1.01e-22$ and $p = 5.84e-13$, respectively). Finally, in NTR there was a self-control factor that was associated with CADM2 ($p = 2.28e-08$).

Thus, there were three risk behavior factors that could be used for the mediation analyses, all extracted from the UKB. There was only one measure of self-control included in the UKB, namely, risk-taking proneness (yes/no). Results of the analysis using this measure
| Variable                                      | 25Up       | S4S        | NTR       | UKB       | Meta-analysis |
|----------------------------------------------|------------|------------|-----------|-----------|---------------|
|                                              | p   | N   | p   | N   | p   | N   | p   | N   | p   | N   | p   | N   | % $R^2$ top | #SNPs | % $R^2$ |
| **Lifetime substance use**                   |          |          |          |          |          |          |          |          |          |          |          |          |          |          |          |
| Ever used tobacco                            | 0.919    | 2,071    | 0.601    | 2,279    | **0.002** | 9,432    | **1.12e-20** | 348,237 | **2.23e-21** | 362,018 | 0.18% | 63 | 0.78%     |
| Ever used cannabis                           | 0.424    | 2,061    | 0.502    | 2,374    | **0.008** | 8,022    | **2.30e-17** | 128,132 | **3.51e-18** | 140,588 | 0.06% | 83 | 2.28%     |
| Ever used other substance(s)                 | 0.858    | 2,008    | 0.184    | 2,380    | 0.179    | 8,073    | -          | -          | 0.241    | 12,460 |
| **Age at initiation of substance use**       |          |          |          |          |          |          |          |          |          |          |          |          |          |          |          |
| Age alcohol initiation                       | 0.818    | 1,940    | 0.887    | 2,048    | **0.049** | 7,784    | -          | -          | 0.318    | 11,772 |
| Age tobacco initiation                       | 0.929    | 458      | 0.737    | 1,343    | 0.370    | 5,664    | 0.444      | 23,423    | 0.519    | 30,888 |
| Age cannabis initiation                      | 0.587    | 1,247    | 0.139    | 1,130    | 0.820    | 1,877    | -          | -          | 0.568    | 4,254  |
| Age other substance initiation               | 0.172    | 1,010    | 0.922    | 503      | 0.443    | 581      | -          | -          | 0.485    | 2,094  |
| **Average substance use**                   |          |          |          |          |          |          |          |          |          |          |          |          |          |          |          |
| Average alcohol units                        | 0.678    | 1,876    | 0.274    | 2,169    | 0.020    | 7,211    | **1.71e-07** | 257,221 | **1.35e-07** | 268,477 | 0.01% | 69 | 0.17%     |
| Average cigarettes per day                  | **0.021** | 419      | 0.177    | 1,242    | 0.042    | 4,016    | **0.002**  | 100,604   | **0.001** | 106,281 | 0.01% | 53 | 0.27%     |
| Average tobacco using days                   | 0.178    | 419      | 0.632    | 1,505    | 0.216    | 1,633    | -          | -          | 0.264    | 3,557  |
| **Regular substance (ab)use**                |          |          |          |          |          |          |          |          |          |          |          |          |          |          |          |
| Regular alcohol use                          | 0.605    | 2,007    | **0.010** | 2,275    | 0.076    | 8,927    | **4.07e-04** | 128,294 | **6.95e-05** | 141,503 | 0.04% | 52 | 0.07%     |
| Problematic alcohol use (AUDIT)              | -        | -        | 0.351    | 2,151    | 0.536    | 5,369    | **8.52e-12** | 128,286 | **2.50e-11** | 135,806 | 0.02% | 67 | 0.31%     |
| Regular tobacco use                          | 0.787    | 1,455    | 0.829    | 2,384    | **0.021** | 6,634    | **5.10e-20** | 240,850 | **5.84e-20** | 251,323 | 0.02% | 90 | 1.22%     |
| Nicotine dependence (FTND)                   | -        | -        | **0.047** | 1,330    | 0.546    | 3,831    | **7.37e-05** | 100,730 | **5.50e-05** | 105,891 | 0.01% | 59 | 0.31%     |
| Regular cannabis use                         | 0.710    | 1,288    | 0.155    | 2,373    | 0.999    | 1,216    | **0.033**  | 28,800    | 0.110    | 33,677 | 0.04% | 50 | 3.02%     |
| Any behavioral/substance addiction           | -        | -        | -        | -        | -        | -        | **0.001**  | 126,817   | -        | -      | 0.04% | 37 | 0.66%     |
| **Sexual risk behavior**                     |          |          |          |          |          |          |          |          |          |          |          |          |          |          |          |
| Number of sexual partners                    | **0.023** | 1,677    | 0.468    | 997      | -        | -        | **2.31e-06** | 295,706   | **1.21e-06** | 298,380 | 0.01% | 54 | 0.12%     |
| Sexual risk behavior                         | 0.673    | 1,873    | 0.529    | 990      | -        | -        | -          | -          | 0.657    | 2,863  |
| Age at first sexual intercourse              | -        | -        | 0.173    | 896      | 0.416    | 941      | **2.86e-18** | 315,749   | **2.08e-18** | 317,586 | 0.02% | 91 | 0.30%     |
as a mediator between CADM2 and the three risk-taking behavior factors are presented in Figure 1 (with p-values rather than regression weights as MAGMA does not provide such estimates). Path $a$ for the association between CADM2 and risk-taking proneness controlling for sex, age, and PCs was tested earlier and found to be significant (see Table 2). Paths $c1$–$c3$ for the associations between CADM2 and the outcomes (risk behavior factors) were reported in Table 3. Paths $b1$–$b3$ between risk-taking proneness and the risk behavior factors were all significant ($tobacco \ (ab\ use\ factor\ OR = 1.27, p < .001;\ lifetime\ smoking\ factor,\ OR = 1.27, p < .001;\ and\ alcohol\ abuse\ factor\ OR = 1.21, p < .001$). In step $c'$, the associations between CADM2 and lifetime smoking and risky alcohol use factors were attenuated when including the mediator ($p = 1.01e-22$ to $1.51e-18$ and $5.84e-13$ to $5.05e-09$, respectively), suggesting partial mediation by risk-taking proneness. The association between tobacco (ab)use and CADM2 was enhanced ($p = 4.34e-05$ to $9.14e-07$) when controlling for risk-taking proneness, which suggests that there was no mediation effect.

4 | DISCUSSION

In this multi-cohort study, it was shown that CADM2 is associated with multiple substance use and abuse traits, sex-related risky behavior, and different indices of self-control. Meta-analyses showed significant associations between CADM2 and lifetime experience with tobacco and cannabis use, average alcohol and cigarette consumption, regular/problematic alcohol and tobacco use, number of sexual partners, age at first sexual intercourse, and disinhibition. Furthermore, in the per-sample analyses there were significant associations with sensation seeking, behavioral or substance addiction, and risk-taking proneness. The variance explained by a single CADM2 SNP ranged from 0.01% (for average alcohol consumption, cigarettes per day, nicotine dependence, and the number of sexual partners) to 0.26% (sensation seeking). Independent top SNPs together explained between 0.07% (regular alcohol use) and 3.02% (regular cannabis use) of the variance. Finally, the self-control trait “risk-taking proneness” was found to be a significant partial mediator of the associations between CADM2 and latent factors for lifetime smoking and regular alcohol use.

The results of this study are in line with results from recent GWAS, indicating associations of CADM2 with substance use and abuse (including alcohol consumption, lifetime cannabis use, and general drug experimentation), sexual risk behavior (such as age at first sexual intercourse and number of sexual partners), and different aspects of self-control (sensation seeking, hyperactivity, and risk-taking propensity). Our study finds support for these findings in a large, hypothesis-driven, multi-cohort and phenotype-wide study for risk behavior, indicating that the role of CADM2 in risky behaviors and reduced self-control is robust. This is also in line with some earlier reported genetic correlations for various forms of risky behaviors, suggesting overlapping genes directly or indirectly influence these behaviors. The observed mediation effect of risk-taking
Table 3 Results for gene-based analyses between CADM2 and factors from the Principal Components Analyses

| Factor                      | Meta-analysis | S4S | NTR | UKB        |
|-----------------------------|---------------|-----|-----|------------|
|                             | p  | N     | p  | N         | p        | N         | p        | N        | p        | N         | p        |
| Lifetime substance usea     | 0.581 | 2076 | 0.733 | 2,389 | 0.723 | 4,445 | 0.09% | 12 | 0.58% |
| Tobacco (ab)useb           | 0.057 | 2076 | 0.085 | 2,389 | 0.084 | 9,471 | 0.13% | 44 | 2.47% |
| Lifetime smokingc         | 0.02% | 80 | 0.24% | 44 | 0.24% | 44 | 2.76% |
| Risky alcohol use           | 0.01% | 80 | 0.24% | 44 | 0.01% | 80 | 0.24% |
| Self-control               | 0.02% | 80 | 0.24% | 44 | 0.02% | 80 | 0.24% |

Note: Factors were extracted if they had an eigenvalue above 1 and explained 3.1% of the variance in the data, resulting in five factors in total, of which two could be detected in multiple cohorts. Below the table, the factor indicators (variables with factor loading >0.4 on the factor) per sample are given.

Abbreviations: 25Up, 25 and Up; NTR, Netherlands Twin Register; MAGMA, Multi-marker Analysis of Genomic Annotation; S4S, Spit for Science; SNP, single nucleotide polymorphism; UKB, UK Biobank.

Averdends et al. 2021

Figure S2. This is a region containing large numbers of expression quantitative trait loci (eQTLs; panel C). eQTLs are places in the genome that influence to what extent a gene comes to expression, that is, how much is transcribed to messenger RNA. Only a few SNPs are among the top 10 independent SNPs for more than one phenotype. This suggests that the effects of CADM2 were not driven by one strong causal SNP. Six SNPs were associated with three different (but overlapping) primary phenotypes (sensation seeking, any behavioral/substance addiction, and risk-taking proneness). Another SNP that was a top SNP more than twice was rs1271459, associated with ever tobacco use, regular tobacco use, and age at first sexual intercourse. SNPs associated with multiple distinct phenotypes might be more central to the functioning of the gene. As an illustration, we looked up this rs1271459. No information was available for this SNP itself, but its proxy rs9820373 is a significant eQTL for CADM2 expression in the subcutaneous adipose tissue (p = 5.4E-4). This is interesting as CADM2 has been associated with BMI, potentially through impulsive over-eating.

4.1 Strengths and limitations

This study has to be viewed in light of its strengths and limitations. Data from separate cohorts with different characteristics were used, which results in a large sample size and high generalizability. It also induces measure heterogeneity, which on the one hand may have limited the power to detect effects in the meta-analyses and on the other hand further substantiates the robustness of findings. This study included a range of risky behavior and self-control phenotypes, potentially expanding the findings. Furthermore, previous research also indicates that CADM2 may play a role in phenotypically heterogeneous
risk-taking behaviors and personality. [1,2,3] Future studies might further explore the role of CADM2 in other potentially related phenotypes, such as (a lack of) physical activity, eating patterns or overweight, gambling, and reckless driving [2] and should investigate if these results generalize to populations with different age ranges or different genetic ancestry.

In this study, we observed explained variances between 0.01% and 3.02%. The 25UP and S4S samples were too small to detect significant effects in the individual samples. Virtually all phenotypes reached significance only after adding data from the larger samples (NTR and UKB). The comparison of four cohorts with different sample sizes has shown that in general samples of over 7,000 individuals are needed to find significant effects with these effect sizes (see Figure S1). [4,5,49] This means that for the phenotypes that were available in UK Biobank, the addition of the other samples has not led to a substantial increase in information over and above what we already learned from previous studies. This is the first study to our knowledge, using this method to give a concrete indication of what sample sizes are needed to detect the effect of a single gene. We may conclude that we must be cautious to draw conclusions from individual small samples, but that these smaller samples can be combined in meta-analyses, especially for (possibly more detailed) phenotypes that are not available in large-scale data sets.

This is the first study aiming to shed light on effect sizes that can be expected on the level of genes. Although small, these effects are substantially larger than those of single variants, as have traditionally been investigated in candidate-gene research. Also, given that behavior arises as a result of a complex interplay between environment and a large number of genes with small effects, the effect sizes of CADM2 that we find could actually be considered substantial. Looking at the level of genes rather than SNPs is biologically more meaningful and could provide clues on underlying biological mechanisms, which in turn will contribute to a better understanding of transgenerational transmission of risky behaviors and provide clues for designing treatment and prevention programs.

This study shows the feasibility and added value of novel variations of the more common analyses in the field of behavior genetics, including genetic association analyses on factor analyzed traits and mediation analyses. New questions might be answered using such techniques, providing more insight into underlying common vulnerability patterns and etiological mechanisms. However, there were some limitations to the mediation analyses, including the lack of control for family relatedness and covariates in the Principal Components Analyses and the impossibility of calculating regression weights for the associations with CADM2. Also, we used Baron and Kenny's procedure to test for mediation only for outcomes that showed a significant relationship with CADM2. [4,7] Technically, mediation could arise in the absence of such a relationship. Bootstrapping is a more recently developed non-parametric method that can increase power to detect mediation. However, this approach has not yet been implemented in the area of genetic association analysis. Future research might develop techniques to tackle these limitations. In conclusion, the mediation results in this study suggest that mediation testing may be feasible, but improved statistical tools applicable to behavioral genetics need to be developed.

Next to the genetic etiology of risk behaviors, we recognize the generally known influence of environmental factors. [13] For example, cultural, parenting or peer norms can influence substance- and sex-related risky behaviors. What remains largely unknown is to what extent the impact of genetic and environmental risks is additive or interactive. The variants in CADM2 identified here lend themselves well to future gene-environment interaction testing, provided a multi-cohort study and a combined SNP measure are used to ensure sufficient power.

5 | CONCLUSIONS

This comprehensive multi-cohort study has shown the feasibility of a PHeWAS for risky behavior to confirm previous findings on associations between CADM2 and manifestations of risky behavior and reduced self-control from GWASs on individual phenotypes. It was shown that single SNPs in CADM2 could explain 0.01% to 0.26% of the variance and a combination of independent top SNPs together 0.07% to 3.02%. This study provides more insight into the relatively small effect sizes that can be expected from association studies. Furthermore, results revealed that a self-control trait might partially mediate the associations between CADM2 and substance-related risky behavior (lifetime smoking and regular alcohol use). Future studies should further explore the biological underpinnings of the observed relationships between CADM2, reduced self-control, and various risky behaviors.

ACKNOWLEDGEMENTS

This study has been conducted using four databases including the 25 and Up, Spit for Science, Netherlands Twin Register, and the UK Biobank. We want to thank all participants and the individuals who contributed to the inclusion, data collection, and data distribution. A special thanks to Ward de Witte, Nina Moth-Rota, and Barbara Franke for helping with requesting and providing the UK Biobank data. Tissue-specific gene expression results mentioned in the discussion and Figure S2C were obtained from the Genotype-Tissue Expression (GTEx) Project (retrieved on 12/05/2019). This project was supported by the Common Fund of the Office of the Director of the National Institutes of Health and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. K.J.H.V. is supported by the Foundation Volksbond Rotterdam and by a grant from Amsterdam Neuroscience. Spit for Science has been supported by Virginia Commonwealth University, P20 AA017828, R37AA011408, K02AA018755, P50 AA022537; K01AA024152 from the National Institute on Alcohol Abuse and Alcoholism; and UL1RR031990 from the National Center for Research Resources and National Institutes of Health Roadmap for Medical Research. This research was also supported by the National Institute on Drug Abuse of the National Institutes of Health (NIH) under Award U54DA036105 and the Center for Tobacco Products of the U.S. Food and Drug
Administration (FDA). The 25up study was funded by the National Health and Medical Research Council Project Grant APP1069141 to IBH and NGM.

CONFLICT OF INTEREST
None of the other authors have any conflicts of interest to report.

AUTHORS CONTRIBUTION
All authors contributed to this work. JMV, AFAS, and KJHV initiated and designed the study. RMA and JAP wrote the major parts of the manuscript under the close supervision of AFAS and JMV. RMA organized and cleaned the 25Up data; JAP organized, cleaned, and analyzed the other cohorts (S4S, NTR, and UKB). EMD guided and advised during parts of the data analyses. Furthermore, SDG, IH, NST, BPZ, MDvdZ, BLM, NGM, BF, EJCdG, DIB, DMD, and NAG contributed to the data collection of individual samples, data sharing, and conceptual shaping of the research and manuscript. All authors were involved in reading and reviewing the final manuscript and approved the final submitted documents.

ORCID
Rachel M. Arends https://orcid.org/0000-0001-6170-4018
Joëlle A. Pasman https://orcid.org/0000-0001-7558-0482

REFERENCES
1. Pasman JA, Verweij KJ, Gerring Z, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nat Neurosci. 2018;21(9):1161-1170.
2. Gore FM, Bloem PJ, Patton GC, et al. Global burden of disease in young people aged 10–24 years: a systematic analysis. Lancet. 2011;377(9783):2093-2102.
3. Baban A, Craciun C. Changing health-risk behaviors: a review of the- nences on impulsivity: a meta-analysis of twin, family and adoption studies. Clin Psychol Rev. 2011;31(7):1209-1223.
4. Bayramak Ö, Pütter C, Volckmar AL, et al. Common obesity risk alleles of CADM2 and MSRA genes on human behavior. Heliyon. 2017;3(7):e00349.
5. Day FR, Helgason H, Chasman DI, et al. Physical and neurobehavioral determinants of reproductive onsets and success. Am J Psychiatry. 2005;162(4):295-305.
6. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2008;126(1):51-90.
7. Kwon JM, Goate AM. The candidate gene approach. Alcohol Res Health. 2000;24(3):164-168.
8. Boutwell B, Hinds D, Agee M, et al. Replication and characterization of CADM2 and MSRA genes on human behavior. PLoS Med. 2004;1(1):e27.
9. Tyndale RF. Genetics of alcohol and tobacco use in humans. Ann Med. 2003;35(2):94-121.
10. Vink JM, Willemsen G, Boomsma DI. Heritability of smoking initiation and nicotine dependence. Behav Genet. 2005;35(4):397-406.
11. Verweij KJ, Zietsch BP, Lysney MT, et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta- analysis of twin studies. Addiction. 2010;105(3):417-430.
34. Dick D, Nasim A, Edwards AC, et al. Spit for science: launching a longitudinal study of genetic and environmental influences on substance use and emotional health at a large US university. Front Gen. 2014; 5:47.
35. Willemsen G, Vink JM, Abdellaoui A, et al. The adult Netherlands twin register: twenty-five years of survey and biological data collection. Twin Res Hum Genet. 2013;16(1):271-281.
36. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3): e1001779.
37. The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68-74.
38. Wagner WE III. Using IBM® SPSS® Statistics for Research Methods and Social Science Statistics. Sage Publications; 2019.
39. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4(7):1-16.
40. Strawbridge RJ, Ward J, Cullen B, et al. Genome-wide analysis of self-reported risk-taking behaviour and cross-disorder genetic correlations in the UK Biobank cohort. Transl Psychiatry. 2018;8(39):1-11.
41. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comp Biol. 2015;11(4):1-19, e1004219.
42. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol. 1995;57(1):289-300.
43. Team RC. R language definition. 2000.
44. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190-2191.
45. Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G* Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149-1160.
46. Fabrigar LR, Wegener DT. Exploratory Factor Analysis. New York: Oxford University Press; 2012.
47. Baron RM, Kenny DA. The moderator–mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173-1182.
48. Hayes AF. Beyond Baron and Kenny: statistical mediation analysis in the new millennium. Commun Monogr. 2009;76(4):408-420.
49. Stringer S, Minica C, Verweij KJ, et al. Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the international cannabis consortium. Transl Psychiatry. 2016;6(3):1-9, e769.
50. The Human Protein Atlas - CADM2. https://www.proteinatlas.org/ENSG00000175161-CADM2/tissue. Accessed on 13th of November 2019.
51. Gläscher J, Adolphs R, Damasio H, et al. Lesion mapping of cognitive control and value-based decision making in the prefrontal cortex. Proc Natl Acad Sci. 2012;109(36):14681-14686.
52. Van Leijenhorst L, Zanolie K, Van Meel CS, Westenberg PM, Rombouts SA, Crane EA. What motivates the adolescent? Brain regions mediating reward sensitivity across adolescence. Cereb Cortex. 2010;20(1):61-69.
53. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4(6):215-222.
54. Haber SN. The place of dopamine in the cortico-basal ganglia circuit. Neuroscience. 2014;282:248-257.
55. GTExConsortium. Variant Page. https://www.gtexportal.org/home/snp/rs4637303. Published 2019. Accessed.
56. Berndt SI, Gustafsson S, Mågi R, et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet. 2013;45(5):501-512.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.